These QD formulations demonstrate enhanced sensitivity and selectivity in detecting biomarkers such as beta-hCG, P53, HER2/neu, and EpCAM, enabling the accurate assessment and imaging of breast cancer cells. This evidence concerns the gene TP53 and breast carcinoma.